Cangrelor’s Second Advisory Committee Could Be The Charm
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA reviewers again recommended approval of the antiplatelet, but this time there doesn’t appear to be opposition from the team leader.
You may also be interested in...
Cangrelor Can’t Escape Its Past At FDA Advisory Committee
The Medicines Co.’s anti-clotting drug had one relatively positive study, but two failed ones, and that produced two lopsided “no” votes by the Cardiovascular and Renal Drugs Advisory Committee.
Cangrelor’s Approval Prospects: FDA Reviewers Say Yes, Team Leader Says No
As The Medicines Co.’s anticlotting drug heads to the Cardiovascular and Renal Drugs Advisory Committee, questions about comparator dosing and timing and the severity of bleeding events will be on the agenda.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.